Origin of NME licensed or acquired by company size 2014-2018

Veuillez noter que la page demandée n’est pas disponible dans la langue par défaut sélectionnée. Vous utilisez notre plateforme dans une autre langue maintenant.

Of the FDA approved drugs in the period 2014-2018, 71 percent that were licensed or acquired originated from a smaller biopharma company. This statistic presents the percentage of origin of FDA-approved new drugs from 2014 to 2018 that were licensed or acquired, by company size.

Origin of FDA approved new drugs from 2014 to 2018 that were licensed or acquired, by company size*

Characteristic	Percentage of drugs licensed or acquired
Smaller	71%
Mid-Sized	13%
Large	7%
Top 10 Pharma	9%

Loading statistic...

Download

Source

Show detailed source information?

Already a member?

Sources

Use Ask Statista Research Service

Release date

January 2019

More information

Region

United States

Survey time period

2014 to 2018

Supplementary notes

* Note:
“ Top 10 pharma companies ”: Pharma companies ranked within the top ten worldwide by pharma sales.
“ Other large biopharma companies ”: Biopharma companies ranked between 11 and 30 in terms of worldwide sales.
“ Mid sized biopharma companies ”: Companies with significant sales of usually between $100 million and $1.
“ Smaller biopharma companies ”: = Other smaller biopharma companies.

Citation formats